Vaishali Pharma Ltd

NSE:VAISHALI (India)  
₹ 168.25 (-0.44%) May 13
On watch
34.63
P/B:
4.28
Market Cap:
₹ 1.77B ($ 21.25M)
Enterprise V:
₹ 1.80B ($ 21.61M)
Volume:
195.50K
Avg Vol (2M):
149.13K
Warning! GuruFocus detected 1 Severe warning sign with VAISHALI. Try a 7-Day Free Trial to check it out.
Volume:
195.50K
Market Cap ₹:
1.77B
Market Cap $:
21.25M
34.63
Avg Vol (2M):
149.13K
Enterprise Value ₹:
1.80B
Enterprise Value $:
21.61M
PB Ratio:
4.28
Alerts Website Sources Stock PDF
Dataset
Financial Download Manual of Stocksâ„¢

Business Description

Vaishali Pharma Ltd

ISIN : INE972X01014
http://www.vaishalipharma.com
R.C. Patel Road, Off Sodawala Lane, 706-709, 7th Floor, Aravalli Business Center, Borivili (West), Mumbai, MH, IND, 400092
Compare
Compare
BOM:537536BOM:524824BOM:524518BOM:532878NSE:SOTACBOM:531173BOM:532637BOM:540702BOM:531569BOM:524828ZTSXTER:MRKTSE:4502LSE:HLNNSE:SUNPHARMATSE:4523TSE:4507SZSE:000538XSWX:SDZHKSE:03692
Traded in other countries / regions
VAISHALI.India
IPO Date
2017-08-22
Description
Vaishali Pharma Ltd is a pharmaceutical company. The company is engaged in the business of trading (including exports) pharmaceuticals products. It mainly deals in Active Pharmaceutical Ingredient, pharmaceutical formulations, surgical products, Herbal and Nutraceutical Products, and veterinary supplements operating in the domestic and export market.

Financial Strength

7/10
Name Current Vs Industry Vs History
Cash-To-Debt 0.8
Equity-to-Asset 0.55
Debt-to-Equity 0.34
Debt-to-EBITDA 1.42
Interest Coverage 4.02
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.97
Distress
Grey
Safe
Beneish M-Score -2.32
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

5/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 1
3-Year EBITDA Growth Rate 52.7
3-Year EPS without NRI Growth Rate 28.3
3-Year FCF Growth Rate -38.4
3-Year Book Growth Rate 23.8

Momentum Rank

2/10
Name Current Vs Industry Vs History
5-Day RSI 72.21
9-Day RSI 66.16
14-Day RSI 61.9
6-1 Month Momentum % 17.45
12-1 Month Momentum % 14.75

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.42
Quick Ratio 2.39
Cash Ratio 0.39
Days Inventory 11.23
Days Sales Outstanding 262.73
Days Payable 89.66

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield % 3.04

Profitability Rank

6/10
Name Current Vs Industry Vs History
Gross Margin % 11.25
Operating Margin % 11.48
Net Margin % 7.86
FCF Margin % 1.05
ROE % 15.27
ROA % 7.49
ROIC % 12.4
ROC (Joel Greenblatt) % 26.35
ROCE % 23.27
Years of Profitability over Past 10-Year 9

GF Value Rank

5/10
Name Current Vs Industry Vs History
PE Ratio 34.63
PE Ratio without NRI 34.63
Shiller PE Ratio 114.95
PEG Ratio 1.72
PS Ratio 2.65
PB Ratio 4.28
Price-to-Tangible-Book 4.34
Price-to-Free-Cash-Flow 241.43
Price-to-Operating-Cash-Flow 174.95
EV-to-EBIT 17.89
EV-to-EBITDA 17.02
EV-to-Revenue 2.43
EV-to-FCF 231.67
Price-to-Projected-FCF 5.56
Price-to-Peter-Lynch-Fair-Value 1.41
Price-to-Graham-Number 2.43
Price-to-Net-Current-Asset-Value 4.94
Earnings Yield (Greenblatt) % 5.58
FCF Yield % 0.44
Forward Rate of Return (Yacktman) % 19.89
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Vaishali Pharma Ltd Executives

Details

GF Value: ₹88.52

NSE:VAISHALI

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₹) 742.831
EPS (TTM) (₹) 4.88
Beta -0.31
Volatility % 46.64
14-Day RSI 61.9
14-Day ATR (₹) 8.122992
20-Day SMA (₹) 161.63
12-1 Month Momentum % 14.75
52-Week Range (₹) 114.85 - 203.6
Shares Outstanding (Mil) 10.55

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Vaishali Pharma Ltd Filings

Filing Date Document Date Form
No Filing Data

Vaishali Pharma Ltd Stock Events

Financials Calendars
Event Date Price(₹)
No Event Data

Vaishali Pharma Ltd Frequently Asked Questions

What is Vaishali Pharma Ltd(NSE:VAISHALI)'s stock price today?
The current price of NSE:VAISHALI is ₹168.25. The 52 week high of NSE:VAISHALI is ₹203.60 and 52 week low is ₹114.85.
When is next earnings date of Vaishali Pharma Ltd(NSE:VAISHALI)?
The next earnings date of Vaishali Pharma Ltd(NSE:VAISHALI) is .
Does Vaishali Pharma Ltd(NSE:VAISHALI) pay dividends? If so, how much?
Vaishali Pharma Ltd(NSE:VAISHALI) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.